 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...1617181920212223242526...858859» |
- || Enbrel (etanercept) / Pfizer, Amgen
Review, Journal: Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review. (Pubmed Central) - Nov 4, 2024
The patient recovered after treatments with steroids, macrolides, immunoglobulins, and etanercept, along with repeated removal of scabs via bronchoscopy...The mucocutaneous toxicity induced by PD-1 monoclonal antibodies is not limited to the surface of the skin but also in deep mucosal layers, potentially leading to life-threatening complications. Therefore, when using PD-1 monoclonal antibodies, clinicians should closely monitor adverse events and apply appropriate treatments as soon as possible to prevent severe complications.
- | Prolia (denosumab) / Amgen
Journal: Dental Hygienists' Awareness of Medication-Related Osteonecrosis of the Jaw in Private Dental Clinics in Japan. (Pubmed Central) - Nov 4, 2024
Purpose: Medication-related osteonecrosis of the jaw (MRONJ) caused by bisphosphonates (BPs) and denosumab (Dmab) is still a major oral adverse event caused by cancer treatment and may be under-recognized by private dental services...In addition, few private clinic DHs were aware of MRONJ cases refractory to antibiotic treatment alone (p?=?.012). These findings suggest that private clinic DHs have less knowledge of MRONJ than those in cancer base hospitals.
- | Stivarga (regorafenib) / Bayer
Journal: Electrostatic spraying for fine-tuning particle dimensions to enhance oral bioavailability of poorly water-soluble drugs. (Pubmed Central) - Nov 4, 2024
Regorafenib (1 g), as a model drug, copovidone (5 g), and sodium dodecyl sulfate (0.1 g) were dissolved in 200 ml ethanol and subjected to conventional-spray-dryer and electrostatic spray dryer...Furthermore, ESDN substantially improved oral bioavailability and antitumor efficacy compared to CSDN. These findings suggest that ESD shows potential in developing enhanced drug delivery systems for poorly water-soluble drugs, effectively addressing the limitations associated with CSD methods.
- | Neulasta (pegfilgrastim) / Roche
Preclinical, Journal: Aggregation of human plasma and of human blood induced in vitro by pegfilgrastim originator formulation buffer and pegfilgrastim products. (Pubmed Central) - Nov 4, 2024
These findings suggest that ESD shows potential in developing enhanced drug delivery systems for poorly water-soluble drugs, effectively addressing the limitations associated with CSD methods. We herein report that solutions of pegfilgrastim originator product Neulasta
- | Epogen (epoetin alfa) / Amgen
Trial completion date: Pharmacological Countermeasures for High Altitude (clinicaltrials.gov) - Nov 4, 2024
P4, N=18, Active, not recruiting, Sponsor: United States Army Research Institute of Environmental Medicine
We herein report that solutions of pegfilgrastim originator product Neulasta Trial completion date: Sep 2024 --> Dec 2024
- ||| briquilimab (JSP191) / Jasper Therap
Enrollment change, Trial completion date, Trial primary completion date: SPOTLIGHT: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (clinicaltrials.gov) - Nov 4, 2024
P1/2, N=27, Recruiting, Sponsor: Jasper Therapeutics, Inc.
Trial completion date: Sep 2024 --> Dec 2024 N=18 --> 27 | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Nov 2025
- | carboplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Nov 4, 2024
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=18 --> 27 | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Nov 2025 Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors (clinicaltrials.gov) - Nov 4, 2024
P=N/A, N=100, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- || Inpefa (sotagliflozin) / Lexicon Pharma, volagidemab (REMD-477) / Amgen, REMD Bio
Enrollment open, Trial completion date, Trial primary completion date: SOTA: Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes (clinicaltrials.gov) - Nov 4, 2024
P1/2, N=24, Recruiting, Sponsor: University of California, San Diego
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Nov 3, 2024
P=N/A, N=517991, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028 Active, not recruiting --> Completed
- ||| Venclexta (venetoclax) / Roche, AbbVie, navitoclax (ABT 263) / AbbVie
Enrollment change, Trial completion date, Trial primary completion date: Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax (clinicaltrials.gov) - Nov 3, 2024
P1/2, N=35, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=98 --> 35 | Trial completion date: Jul 2029 --> Mar 2025 | Trial primary completion date: Aug 2025 --> Jun 2024
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Biomarker, Retrospective data, Journal: Effects of teprotumumab and role of HLA markers in patients with thyroid eye disease. (Pubmed Central) - Nov 3, 2024
HLA may predict responders vs nonresponders. Further studies with longer duration and larger population comparing teprotumumab with steroids or other immunomodulatory agents (tocilizumab, rituximab, etc) may be helpful.
- Prolia (denosumab) / Amgen
Exploring rates of prescribing calcium and vitamin D supplementation in cancer patients receiving bone resorptive agents (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_452;
This small observational study has demonstrated that patient reports of being prescribed calcium and vitamin D supplementation are not aligned with current guidelines. Further research in this space would examine gaps in processes to improve on prescribing rates and optimize patient care.
- Ibrance (palbociclib) / Pfizer
Real-world usage patterns of palbociclib and associated patient characteristics in Australia: a retrospective analysis (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_212;
Subsequent therapies included aromatase inhibitors (54%), fulvestrant (12.9%), everolimus (5.3%) and chemotherapy (54.5%) including capecitabine (32%) and nab-paclitaxel (18.7%). Conclusion This study provides real-world data on the utilisation and outcomes on palbociclib in Australia, offering insights into the management of HR+/HER2- advanced or metastatic breast cancer.
- | Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene
Journal: uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. (Pubmed Central) - Nov 2, 2024
Imaging with either uPAR antibody was found to be more tumor-selective than imaging with [18F]FDG or [18F]F-DPA-714. The use of radiolabeled uPAR-targeting antibodies provides a new antibody-based PET imaging candidate for pancreatic cancer imaging as well as chemotherapy-induced senescence.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2256;
- The addition of ribociclib, palbociclib or abemaciclib to the next generation oral SERD, camizestrant, delivers greater anti-tumour efficacy in a range of ESR1wt and ESR1m breast PDX models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2073;
- Luminal-to-basal subtype conversion is governed by TP53-GATA3 mutational status and is targetable by MAPK inhibition in patients with breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2063;
- Ibrance (palbociclib) / Pfizer
Subtype by PAM50 changes after Neoadjuvant Endocrine therapy, from A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in ER+HER2- Operable Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2024;
- Perjeta (pertuzumab) / Roche
Pertuzumab and Trastuzumab Biosimilars in Real-Life Association for the First-Line Treatment of HER2-Positive Metastatic Breast Cancer: the prospective, observational PETRA study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1977;
- Fablyn (lasofoxifene) / Sermonix, Verzenio (abemaciclib) / Eli Lilly
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1975;
- Concordance Analysis of Non-Invasive determination techniques of PIK3CA and ESR1 mutations in patients with advanced luminal breast cancer. Study CANIPE (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1961;
- Thymidine kinase activity as a prognostic biomarker for first line CDK4/6 inhibitor efficacy in the Personalised Disease Monitoring in Metastatic Breast Cancer study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1960;
- Real world evidence of continued CDK4/CDK6 inhibition and endocrine therapy beyond progression on a prior CDK4/6i in women with hormone receptor positive (HR+), Her2 negative advanced breast cancer (MBC). (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1930;
- Subsequent Treatments After Progression On Cyclin-Dependent Kinase 4/6 Inhibitors - A Multicentric Portuguese Real-world Data Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1928;
- Clinical and pathologic factors associated with progression-free survival in patients with metastatic hormonal breast cancer treated with ICDK4/6 (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1926;
- Molecular characterization of the NeoPalAna Endocrine Resistant (ET-R) Cohort: implications for CDK4/6 inhibitor (CDK4/6i) and ET resistance mechanisms in primary estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC). (Room 221ABC) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1861;
- OKI-219 / OnKure
OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3K? H1047R mutant breast cancer models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1821;
- Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapies in elderly HR+/HER2- metastatic or advanced breast cancer: patient-level network meta-analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1815;
- CDK4/6 inhibitors (iCDK4/6) in breast cancer (BC): Is it possible to predict response? (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1814;
- Endocrine Therapy with or without Cyclin-dependent Kinase 4/6 Inhibitor for HR-Positive, HER-Negative, advanced breast cancer following progression on a prior CDK4/6 Inhibitor plus Endocrine Therapy: A Systematic Review and Meta-Analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1813;
- Prescription patterns and preferences for CDK4/6 inhibitors among oncologists in Latin America (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1806;
- Ibrance (palbociclib) / Pfizer
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1805;
- vepdegestrant (ARV-471) / Arvinas, Pfizer, Verzenio (abemaciclib) / Eli Lilly
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1804;
- Patterns and predictors of disease progression and their impact on survival in patients receiving Cyclin D Kinase 4/6 inhibitors (CDK4/6i) for advanced Breast Cancer (aBC). (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1803;
- BTX-9341 / BioTheryX
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1773;
- Rolvedon (eflapegrastim-xnst) / Assertio
Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1762;
- Ibrance (palbociclib) / Pfizer
Real-world palbociclib dose adjustment and outcomes in HR+/HER2- metastatic breast cancer: Flatiron database analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1755;
- Verzenio (abemaciclib) / Eli Lilly
Abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitors in patients with metastatic hormone-receptor positive breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1753;
- Genomic Profiles of Early Progressors vs Exceptional Responders on CDK4/6i in ER+ HER2- Advanced Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1750;
- BGB-43395 / BeiGene
Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1747;
- Ibrance (palbociclib) / Pfizer
Potential risk factors for health-related quality of life (HRQoL) in palbociclib (PAL) plus endocrine therapy (ET) and ET alone patients with HR+/HER2- advanced breast cancer (ABC): exploratory analysis from 6-month longitudinal study (JBCRG-26) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1744;
- The clinical benefits of CDK 4/6 inhibitors and biomarker interactions on HR+/HER2- advanced breast cancer patients: an updated pairwise meta-analysis of randomized controlled trials and network meta-analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1738;
- Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1706;
- Ibrance (palbociclib) / Pfizer
Phase I Safety and Efficacy Study of Autophagy Inhibition to Augment the Antiproliferative and Biological Effects of Low Dose Palbociclib plus Letrozole in Estrogen Receptor-Positive, HER2-negative Metastatic Breast Cancer (MBC) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1700;
- vepdegestrant (ARV-471) / Arvinas, Pfizer
Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and Everolimus (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1694;
- Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptor-positive, HER2-negative metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1689;
- onvansertib (PCM-075) / Cardiff Oncology, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Onvansertib enhances the anti-tumor efficacy of trastuzumab deruxtecan in CDK4/6 inhibitor-resistant HR+/HER2- breast cancer patient-derived xenograft models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1687;
- rogaratinib (BAY 1163877) / Bayer
Selective activity of rogaratinib in PIK3CA- and ESR1-wild-type, FGFR1/2-amplified hormone receptor-positive breast cancer (HR+/HER2- BC): a co-clinical trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1685;
- giredestrant (GDC-9545) / Roche
pionERA Breast Cancer: Phase 3 study of first-line giredestrant vs fulvestrant, + a CDK4/6 inhibitor, in patients with estrogen receptor+, HER2- locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1682;